Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment

BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform
BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform

Clinical trials in three additional indications for BL-8040 to be initiated in 2015
Development strategy presented today at BioLineRx investor meeting in New York